Corrections

The cholesterol levels by age guide listed an optimal fasting triglyceride of under 100 mg/dL in its triglyceride table, described as a metabolic-health marker and not a treatment target, and cited the American Heart Association's 2011 scientific statement on triglycerides and cardiovascular disease for it, in the table's caption and among its sources. It is the figure we removed from the triglycerides page the same day, for the same reason: we could not open that statement to check its wording. The publisher's site would not give us the text, it is not in PubMed Central, and its PubMed record has no abstract. The guide no longer lists the optimal row or the 2011 statement. Its four ATP III categories, from normal under 150 mg/dL to very high at 500 and above, and the 2026 ACC/AHA guideline's 150 and 175 mg/dL lines are unchanged.

The triglycerides page listed an optimal fasting triglyceride of under 100 mg/dL, described as a marker of metabolic health and not a treatment target, and cited the American Heart Association's 2011 scientific statement on triglycerides and cardiovascular disease for it. We could not open that statement to check its wording: the publisher's site would not give us the text, it is not in PubMed Central, and its PubMed record has no abstract. Neither document the page now rests on names an optimal level. ATP III's lowest category is normal, under 150 mg/dL, and the 2026 ACC/AHA dyslipidemia guideline puts no number on a normal adult triglyceride. The page no longer lists the optimal level, the sentence repeating it, or the 2011 statement among its sources. Its normal, borderline high, high and very high categories and the 2026 guideline's 150 and 175 mg/dL lines are unchanged.

The triglycerides page said a nonfasting triglyceride under 200 mg/dL is consistent with normal or optimal fasting levels and needs no further testing, citing the American Heart Association's 2011 statement. We could not reopen that statement to check its wording, and both current documents draw the nonfasting line lower, at 175 mg/dL: the 2016 European consensus on nonfasting lipid testing flags a nonfasting triglyceride of 175 or higher, and the 2026 ACC/AHA dyslipidemia guideline, which the AHA wrote with the ACC, uses 175 for a nonfasting sample and 150 for a fasting one. A nonfasting 175 to 199 met that line on our own borderline-high page while this sentence called it consistent with normal. The page now gives the 175 line with its sources, and its answer on fasting no longer says a value under 200 needs no further testing.

Our Noom Med page gave the brand-medication track as $39 to start, then $99 a month, and the lowest compounded tier as $199 a month after the first supply, from Noom's pricing page as we read it on September 23, 2026. Read again on October 28, 2026, the same page prints $129 a month for the brand-medication track and $179 a month for the lowest compounded tier. The page now gives the October 28 prices. The other two compounded tiers, at $249 and $299 a month, and the metformin program, at $69 to start and then $99 a month, were unchanged. A footnote the page quoted, describing results from "Noom Med users prescribed compounded GLP-1s", no longer appears on Noom's pricing page, and our page now dates it to September 23.

The breast cancer screening page answered "I was told I have dense breasts. Do I need an ultrasound or MRI too?" with "No body currently recommends it for dense breasts alone." The American College of Radiology does: its 2023 recommendations say "For women with dense breasts who desire supplemental screening, breast MRI is recommended." The answer now says no body recommends extra imaging for everyone with dense breasts, and gives the USPSTF's and the ACR's positions in their own words.

The colorectal cancer screening page said of the American College of Physicians that "ACP suggests, it does not direct." "Suggests" is the wording of ACP's announcement. The guidance statement's own abstract puts the same points as "Clinicians should," including "Clinicians should stop screening for colorectal cancer in asymptomatic average-risk adults older than 75 years." The page now gives both wordings.

The ALT page labeled the American Gastroenterological Association's 2021 fatty liver pathway as "updated for MASLD, March 2026". The 2021 document was not updated: in March 2026 the AGA replaced it with a new pathway. Two pieces of AGA advice on the page came from the 2021 version and had changed. The AGA now suggests repeating a low FIB-4 score every one to two years, not every 2 to 3. It now screens adults with type 2 diabetes, people who are overweight or obese with at least one more metabolic risk factor, and people with fatty liver on imaging or raised liver enzymes. The page now labels the 2021 pathway as replaced, dates its prevalence figures to 2021, and gives the current AGA advice from the AGA's own summary.

Our guide to a high ALT presented the same 2021 pathway as current. Its FIB-4 table advised repeating a low score every 2 to 3 years; it now gives the AGA's current one to two years and labels the 2021 advice as replaced. It applied the older-adult line of 2.0 to people over 65; the AGA now applies it from age 65. It said MASLD affects roughly 37 percent of US adults; that figure is the 2021 pathway's estimate for NAFLD, the condition's former definition, and the guide now says so beside the AGA's current figure of about 30 percent.

The colorectal cancer screening page said all three bodies define average risk by the same exclusions, including a family history of colorectal cancer and past abdominal or pelvic radiation. Only the American Cancer Society lists both. The USPSTF excludes only a family history of a known genetic disorder such as Lynch syndrome, and ACP excludes a family history of colorectal cancer but does not mention radiation. The page also said anyone with one of those histories should not follow any of the rows; ACS says some people with a family history can follow its average-risk recommendations. It also said ACP rejects stool DNA and CT colonography "on the grounds of harms, cost and follow-up burden," a reason neither ACP's announcement nor its abstract gives, and it put a "ten million" figure on screening the 45 to 49 group that we cannot source. The page now gives each body's own definition and ACP's exact words, and says we have not read ACP's full statement.

The lipoprotein(a) page said the conversion between units is about 1 mg/dL to 2.1 to 2.5 nmol/L, and that 50 mg/dL is about 105 to 125 nmol/L. Its source, the European Atherosclerosis Society's 2022 consensus statement, gives neither figure: it calls a factor of 2 to 2.5 only a "best guess", recommends against using any standard factor, and pairs 50 mg/dL with 125 nmol/L in its thresholds. The page also said Lp(a) is 80 to 90% genetic, which this log corrected on another page on October 19 (the EAS says more than 90%), and that PCSK9 inhibitors lower it 20 to 25% (the EAS says 15 to 30%). All three now say what the EAS says.

The lung cancer screening page's search description said all three recommending bodies start at 50 and 20 pack-years. The USPSTF and the American Cancer Society do; CHEST's strong recommendation covers 55 to 77 with 30 pack-years, and only its weak recommendation starts at 50 and 20. The page also said all three bodies end screening for someone who would not want treatment; CHEST does not name it, and recommends against screening only when health problems limit both life expectancy and the ability to tolerate follow-up tests or treatment. Both sentences now say what each body says.

Four of these pages cited sources that no longer set their numbers: the 2001 ATP III cholesterol classification, the 2018 cholesterol guideline that the 2026 ACC/AHA dyslipidemia guideline replaced, 2003 hs-CRP tiers we could not verify, 2019 European goals we could not read and, for total cholesterol, MedlinePlus, which does not set a range. They now rest on the 2026 dyslipidemia guideline, which moved the ApoB risk enhancer from 130 to 120 mg/dL. The total cholesterol page now says plainly that no current US guideline sets a range for it.

The blood pressure page already cited the 2025 AHA/ACC guideline but had three false sentences. It called under 120/80 the goal; the guideline's treatment goal for adults with high blood pressure is under 130/80. It said a reading falls into a category when either number qualifies; normal and elevated need both. It gave a screening schedule USPSTF does not set, and now quotes USPSTF's. The page also lacked the severe band (higher than 180 and/or 120) and now has it, with the symptoms that mean calling 911. The box where a reader types a reading now says it takes the systolic number, because a diastolic 95 typed into it was banded as normal.

Seven guides and hubs still repeated the retired cholesterol and blood pressure figures. They now agree with the corrected pages above, and the 2001 ATP III bands appear only where the page says they are retired. One of them said Lp(a) is roughly 80 to 90% genetic; the European Atherosclerosis Society says more than 90%.

Where a body leaves screening or vaccination to an individual decision, the age chart drew that window the same way as a recommendation. CDC's HPV vaccination window from 27 to 45 and USPSTF's grade C on prostate screening read as advice to act, and so did six similar rows on the colorectal, breast, prostate and abdominal aortic aneurysm pages. All eight are now drawn and labeled as individual decisions.

We printed $99 a month for semaglutide and $149 for tirzepatide, the prices CoreAge's product pages showed when we read them on September 26. On October 13 those pages headlined $79 and $129, while the menu on the same pages still read semaglutide "starting at $99/mo". The page now gives both and says which says what.

Rows with no age range were labeled "Not age-bounded", which read as "screen at any age" on rows where USPSTF recommends against screening or found the evidence insufficient: abdominal aortic aneurysm screening in women who have never smoked, and chlamydia and gonorrhea screening in sexually active men. Those rows now state what USPSTF concluded.

Our Medical Advisory Board pages said licensed clinicians review our content and that every clinical article is reviewed by a licensed clinician separate from the writer. No named clinician reviewed the site. The medical review page now says so, and the words "medically reviewed" appear only on a page a named clinician has reviewed. A write-for-us page that said every piece is medically reviewed was removed.

The erectile dysfunction guide called PDE5 inhibitors such as sildenafil and tadalafil the AUA guideline's first-line option. The guideline says to discuss every treatment that is not contraindicated as a potential first-line option, and the guide now says so. The multivitamin guide said almost every trial enrolled adults 60 and older and that there was essentially no trial evidence for adults 35 to 50. SU.VI.MAX enrolled adults in their 30s and 40s and was overall null, and the guide now names it.

A pop-up shown to readers who were leaving promised one email a week. The site could not send email at all. From September 19 it said we were not sending yet, and since October 19 it no longer opens on its own while we cannot send.

SHED's price was cited to a page that turned out to be a sign-in form with no price on it. It is now cited to SHED's plan table: $199 month to month, $179 a month on 6 months, $159 on 12, with a two-month minimum. Bodybuilding Health+ had changed its prices: $141.50 a month on 12 months (we printed $139), $158 on 6 (we printed $149) and $159.33 on 3 (we printed $159).

For 16 days, BetterHelp buttons read "Get started with 30% off". The offer behind that link was for members of the Phi Kappa Phi honor society, and its landing page greeted readers as members. The buttons now carry BetterHelp's public offer, 20% off the first month, which we confirmed by loading the link and reading the page. BetterHelp ads on our online therapy cost guide still linked to the honor-society offer, under a button that by then read 20% off, and were fixed the next day.

The 60s hub cited its RSV vaccine row to a June 2025 addendum to the CDC adult schedule that had been stayed by a court and was not in force. The row now cites the schedule in force, reviewed July 2, 2025 and amended April 27, 2026 to add ACIP's April 2025 RSV recommendation.

The ApoB vs LDL cholesterol guide linked its National Lipid Association source, which carried the guide's two headline thresholds, to a different paper on access to weight-loss medicines. The link now opens the NLA consensus on apolipoprotein B. The adult ADHD (ASRS), PTSD (PCL-5) and alcohol use (AUDIT) self-tests said a screening questionnaire estimates symptom severity over the last two weeks. The ASRS asks about the past six months, the PCL-5 the past month and the AUDIT the past year, and each test now states its own window.

Use the contact form with the page address, the statement you think is wrong and the source that shows it. We check the claim against the document that sets the number, fix the page if it is wrong, and add the correction here. How pages are written and checked is set out in our editorial standards.